Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AP303 in Diabetic Kidney Disease
NCT06666283Phase 1Recruiting
- Sponsor
- Alebund Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic kidney disease (DKD) comparing AP303 with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration at Day 14, Time to Maximum Concentration at Day 14 and 4 more. Started Feb 2025; status: recruiting.
02
Drugs
AP-303
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06666283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666283.